Clinical trial
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal…
NCT00297687 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00297687 |
|---|---|
| Title | Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults |
| Official title | A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Meningitis, Meningococcal |
| Intervention type | Biological |
| Interventions | MnB rLP2086 |
| Enrollment | 108 |
| Start date | Mar 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Feb 28, 2006 |
| Last update posted | Dec 5, 2007 |
| Countries | Australia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: